Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 18 Glioma 11 Neoplasms 6 Brain Neoplasms 6 Astrocytoma 6 Neuroblastoma 4 Sarcoma, Ewing 3 Gliosarcoma 3 Sarcoma 2 Rhabdomyosarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Medulloblastoma 2 Diffuse Intrinsic Pontine Glioma 2 Wilms Tumor 1 Spinal Cord Neoplasms 1 Rhabdoid Tumor 1 Refractory Solid Tumors 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neuroendocrine Tumors 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasm Metastasis 1 Melanoma, Cutaneous Malignant 1 Melanoma 1 Lymphoma, Follicular 1 Hepatoblastoma 1 Ganglioneuroblastoma 1

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma, Cutaneous Malignant × Temozolomide × 30 days × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡